A5102824000- Lymphoma Diagnosis and Treatment
- Estrogen and related hormone effects
- HER2/EGFR in Cancer Research
- Galectins and Cancer Biology
- Ovarian cancer diagnosis and treatment
- Chronic Lymphocytic Leukemia Research
- Angiogenesis and VEGF in Cancer
- Immune Cell Function and Interaction
Karolinska Institutet
2014-2022
// Gergely Talaber 1 , Konstantin Yakimchuk Jiyu Guan Jose Inzunza Sam Okret Department of Biosciences and Nutrition, Karolinska Institutet, NOVUM, Huddinge, Sweden Correspondence to: Okret, e-mail: sam.okret@ki.se Keywords: lymphoma, sex hormones, androgens, aromatase inhibitor, gender difference Received: November 09, 2015 Accepted: February 20, 2016 Published: March 02, 2016 ABSTRACT Most lymphomas show higher incidence poorer...
Diffuse large B-cell lymphoma (DLBCL) shows a higher incidence in males versus females. Epidemiological studies have shown that female gender is favorable prognostic factor, which may be explained by estrogens. Here we show when grafting human DLBCL cells to immunocompromised mice, tumor growth faster. When treating mice grafted with either germinal center or activated like the selective estrogen receptor β (ERβ) agonist diarylpropionitrile, was significantly inhibited. Furthermore, nuclear...
Mantle cell lymphoma (MCL) is a non-Hodgkin with one of the highest male-to-female incidence ratios. The reason for this not clear, but epidemiological as well experimental data have suggested role estrogens, particularly acting through estrogen receptor β (ESR2). To study ESR2 effects on MCL progression, cells sensitive and resistant to Bruton tyrosine kinase inhibitor ibrutinib were grafted mice treated ESR2-selective agonist diarylpropionitrile (DPN). results showed that DPN treatment...